Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / analysis-veridian-demand-letter-memo.docx
analysis-veridian-demand-letter-memo.docx
Parties
Harkness LLP
Penterra Pharmaceuticals Corp
Cole LLP
See Frontier Oil Corp
Holly Corp
AB Stable VIII LLC
Resorts One LLC
Nat'l Holdings Corp
Dates
October 18, 2024
October 15, 2024
June 10, 2024
September 30, 2024
November 15, 2024
June 14, 2024
May 20, 2024
December 10, 2024
August 14, 2024
August 28, 2024
Amounts
$900,000,000
$45,000,000
$87.3
$112.4
$200
$400
$500
$700
$500,000,000
$2.1
Obligations
Since the date of this Agreement, there shall not have occurred any Material Adverse Effect
2018), and the extensive body of Chancery Court precedent that preceded it, a material adverse effect must be measured against the long-term earnings potential of the company, not merely its short-term performance
The clinical hold must be resolved, additional safety data must be generated at the revised dose, the protocol-amended cohort must be enrolled and followed, and the FDA may require a new Phase II study or a Phase II/III bridging study before permitting Phase III enrollment
However, we must candidly acknowledge the risks
2(b) — that no Material Adverse Effect shall have occurred — is a backward-looking condition that has already failed
Penterra's legal argument is well-supported: the MAE condition looks backward ("shall have occurred"), and subsequent remedial measures do not undo the occurrence of the MAE